Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non–small cell lung cancer patients with impaired renal function: RESTART trial

[1] Gandhi L(2018)Pembrolizumab plus chemotherapy in metastatic non-small-cell lung Cancer N Engl J Med 378 2078-2092

[2] Rodríguez-Abreu D(2019)Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial Lancet Oncol. 20 924-937

[3] Gadgeel S(2021)Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial J Thorac Oncol 16 653-664

[4] Esteban E(2018)Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC N Engl J Med 378 2288-2301

[5] Felip E(2021)First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial Lancet Oncol. 22 198-211

[6] De Angelis F(2012)Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial Lancet Oncol 13 247-255

[7] West H(2020)Treatment rationale and design for APPLE (WJOG11218L): a multicenter, open-label, randomized phase 3 study of Atezolizumab and platinum/Pemetrexed with or without bevacizumab for patients with advanced nonsquamous non-small-cell lung Cancer Clin Lung Cancer. 21 472-476

[8] McCleod M(2005)Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism Clin Pharmacokinet 44 349-366

[9] Hussein M(2014)Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel J Clin Pharmacol 54 1097-1107

[10] Morabito A(2015)Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: analysis of safety and efficacy in patients with renal impairment Clin Lung Cancer 16 112-120

[1] Gandhi L(2018)Pembrolizumab plus chemotherapy in metastatic non-small-cell lung Cancer N Engl J Med 378 2078-2092

[2] Rodríguez-Abreu D(2019)Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial Lancet Oncol. 20 924-937

[3] Gadgeel S(2021)Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial J Thorac Oncol 16 653-664

[4] Esteban E(2018)Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC N Engl J Med 378 2288-2301

[5] Felip E(2021)First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial Lancet Oncol. 22 198-211

[6] De Angelis F(2012)Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial Lancet Oncol 13 247-255

[7] West H(2020)Treatment rationale and design for APPLE (WJOG11218L): a multicenter, open-label, randomized phase 3 study of Atezolizumab and platinum/Pemetrexed with or without bevacizumab for patients with advanced nonsquamous non-small-cell lung Cancer Clin Lung Cancer. 21 472-476

[8] McCleod M(2005)Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism Clin Pharmacokinet 44 349-366

[9] Hussein M(2014)Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel J Clin Pharmacol 54 1097-1107

[10] Morabito A(2015)Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: analysis of safety and efficacy in patients with renal impairment Clin Lung Cancer 16 112-120